PatentAug 11, 2026, 05:09 PM
Vivos Therapeutics Secures New US Patent for CARE Device Technology
AI Summary
Vivos Therapeutics, Inc. announced the issuance of a new US Patent, No. 12,697,190, which broadens the protection for its Vivos CARE oral medical device technology. This continuation patent builds upon a foundational patent from 2024, securing broader, design-independent claims. The company believes this strengthens its intellectual property position, making it more challenging for competitors to circumvent its innovations in treating obstructive sleep apnea (OSA), for which its devices have received unprecedented FDA clearances.
Key Highlights
- Vivos Therapeutics announced the issuance of new US Patent No. 12,697,190.
- The patent broadens protection for the company's Vivos CARE oral medical device technology.
- It is a continuation of US Patent No. 12,048,608, issued July 30, 2024.
- Vivos CARE devices received two FDA 510K clearances in 2023 and 2024 for OSA.
- Studies indicate approximately 80% of patients treated with Vivos CARE devices achieve significant OSA symptom reduction.
- The new patent strengthens Vivos' intellectual property position and competitive advantage.
Price Impact
More from VVOS